Answers are grounded in this paper and cite their sources.
β1,4-galactosylation is a typical human N-glycan formation with functional impact on proteins, particularly known for IgGs. Therefore, the expression of recombinant proteins with controlled galactosylation is an important quality parameter in the biotech industry. Here we describe the establishment of a plant-based expression platform for the manufacturing of recombinant proteins carrying β1,4-galactosylated N-glycans. A genome-edited Nicotiana benthamiana glycosylation mutant (NbXF-KO) that synthesizes conserved eukaryotic GnGn structures served as a template for further elongation toward β1,4-galactosylated N-glycans. A hybrid β1,4-galactosyltransferase gene that targets the enzyme to a post-Golgi compartment was introduced into the NbXF-KO genome without any additional foreign DNA sequence. The efficient generation of “marker-free” transgenic lines (NbXF-KO Gal ) was achieved by using a dual-vector strategy and visual screening procedures. Of note, a monoclonal antibody expressed in NbXF-KO Gal exhibited up to 70 % galactosylated, fucose/xylose-free N-glycans, in a batch-to-batch consistent manner. Given recent findings attributing anti-inflammatory activities to nonfucosylated, galactosylated IgG, our results gain new significance. • Multi-gene-edited knockout Nicotiana benthamiana is suited for stable expansion of plant N-glycosylation. • The platform expresses recombinant proteins carrying fucose-free β1,4-galactosylated N-glycans. • Glycan engineered plants are free of any marker sequences. • A dual-vector strategy allowed efficient generation and screening of marker-free transgenic plants. • Compared to mass spectrometry, a simplified approach was developed to assess the abundance of β1,4-galactosylated N-glycans.
No takes yet. Share an insight, caveat, or question.
Kogelmann et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: